JP7017258B2 - 腫瘍治療のための標的化されたドキソルビシン－金ナノコンジュゲート - Google Patents

腫瘍治療のための標的化されたドキソルビシン－金ナノコンジュゲート Download PDF

Info

Publication number
JP7017258B2
JP7017258B2 JP2019536487A JP2019536487A JP7017258B2 JP 7017258 B2 JP7017258 B2 JP 7017258B2 JP 2019536487 A JP2019536487 A JP 2019536487A JP 2019536487 A JP2019536487 A JP 2019536487A JP 7017258 B2 JP7017258 B2 JP 7017258B2
Authority
JP
Japan
Prior art keywords
nanoconjugate
cancer
weight
dtdtpa
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019536487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504130A5 (enExample
JP2020504130A (ja
Inventor
カンナン、ラフラマン
ザンブレ、アジト
ウペンドラン、アナンディ
Original Assignee
ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ filed Critical ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Publication of JP2020504130A publication Critical patent/JP2020504130A/ja
Publication of JP2020504130A5 publication Critical patent/JP2020504130A5/ja
Application granted granted Critical
Publication of JP7017258B2 publication Critical patent/JP7017258B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019536487A 2017-01-09 2018-01-09 腫瘍治療のための標的化されたドキソルビシン－金ナノコンジュゲート Expired - Fee Related JP7017258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444114P 2017-01-09 2017-01-09
US62/444,114 2017-01-09
PCT/US2018/012882 WO2018129501A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Publications (3)

Publication Number Publication Date
JP2020504130A JP2020504130A (ja) 2020-02-06
JP2020504130A5 JP2020504130A5 (enExample) 2021-02-04
JP7017258B2 true JP7017258B2 (ja) 2022-02-08

Family

ID=62791162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536487A Expired - Fee Related JP7017258B2 (ja) 2017-01-09 2018-01-09 腫瘍治療のための標的化されたドキソルビシン－金ナノコンジュゲート

Country Status (12)

Country Link
US (1) US20210015944A1 (enExample)
EP (1) EP3568694B1 (enExample)
JP (1) JP7017258B2 (enExample)
KR (1) KR102568577B1 (enExample)
CN (1) CN110178028B (enExample)
AU (1) AU2018205349B2 (enExample)
BR (1) BR112019013469A2 (enExample)
CA (1) CA3048908A1 (enExample)
ES (1) ES2912286T3 (enExample)
MX (1) MX2019008233A (enExample)
WO (1) WO2018129501A1 (enExample)
ZA (1) ZA201904736B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797353B (zh) * 2020-06-12 2023-10-20 南京工业大学 一种放化疗联合治疗试剂及其制备方法
CN112494660B (zh) * 2020-12-22 2023-11-21 上海交通大学 纳米靶向药物的制备方法及在治疗胃癌中的应用
US12485484B2 (en) 2022-05-17 2025-12-02 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Seedless synthesis of anisotropic gold nanoflowers with cellular control and drug delivery applications
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates
CN120713846B (zh) * 2025-07-14 2026-03-31 湖南省妇幼保健院 基于铜离子和多柔比星的纳米级配位聚合物NP@DoxCu及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103028A1 (en) 2013-12-30 2015-07-09 The Curators Of The University Of Missouri Au multicomponent nanomaterials and synthesis methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
WO2010014812A2 (en) * 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US9605304B2 (en) * 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
JP6693868B2 (ja) * 2013-02-19 2020-05-13 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ 抗癌化学療法剤用のケージ化された白金ナノクラスタ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103028A1 (en) 2013-12-30 2015-07-09 The Curators Of The University Of Missouri Au multicomponent nanomaterials and synthesis methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2016年，27，1153-1164
European Journal of Medical Chemistry，2011年，46，1857-1860

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치

Also Published As

Publication number Publication date
BR112019013469A2 (pt) 2020-01-07
RU2019125167A (ru) 2021-02-09
ES2912286T3 (es) 2022-05-25
CN110178028B (zh) 2021-04-27
ZA201904736B (en) 2021-04-28
CN110178028A (zh) 2019-08-27
KR102568577B1 (ko) 2023-08-18
US20210015944A1 (en) 2021-01-21
EP3568694B1 (en) 2022-02-16
WO2018129501A1 (en) 2018-07-12
EP3568694A4 (en) 2020-12-30
RU2019125167A3 (enExample) 2021-09-13
MX2019008233A (es) 2019-10-17
AU2018205349A1 (en) 2019-06-27
AU2018205349B2 (en) 2022-09-29
EP3568694A1 (en) 2019-11-20
JP2020504130A (ja) 2020-02-06
CA3048908A1 (en) 2018-07-12
KR20190104333A (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
KR102568577B1 (ko) 종양 요법을 위한 표적화된 독소루비신-금 나노접합체
Singhai et al. CD44 receptor targeted ‘smart’multi-walled carbon nanotubes for synergistic therapy of triple-negative breast cancer
Iannazzo et al. Graphene quantum dots for cancer targeted drug delivery
Botella et al. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation
Bai et al. A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: An in vitro study of targeted delivery of cisplatin to ovarian cancer cells
CN103608139B (zh) 表面改性的重金属纳米粒子、组合物及其用途
Li et al. LHRH-peptide conjugated dextran nanoparticles for targeted delivery of cisplatin to breast cancer
Bartkowski et al. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs
JP2018526432A (ja) ナノ粒子をベースとした肝臓標的化療法および撮像
Wang et al. Peptide-decorated gold nanoparticles via strain-promoted azide–alkyne cycloaddition and post assembly deprotection
EP3576717B1 (en) Nanoparticle-based liver-targeting therapy
Dharmatti et al. Surface orchestration of gold nanoparticles using cysteamine as linke r and folate as navigating molecule for synaphic delivery of doxorubicin
US20190187137A1 (en) Au multicomponent nanomaterials and synthesis methods
JP5873719B2 (ja) 白金含有化合物被覆ナノ粒子を含有するコンジュゲート
Lorenzoni et al. Organoselenium compounds as functionalizing agents for gold nanoparticles in cancer therapy
Chen et al. Dual-targeting SERS-encoded graphene oxide nanocarrier for intracellular co-delivery of doxorubicin and 9-aminoacridine with enhanced combination therapy
Matassini et al. Gold nanoparticles are suitable cores for building tunable iminosugar multivalency
CN106309375A (zh) 一种纳米粒制剂、其制备方法及应用
Alea-Reyes et al. Nanostructured materials for photodynamic therapy: synthesis, characterization and in vitro activity
Botella et al. Effect of drug precursor in cell uptake and cytotoxicity of redox-responsive camptothecin nanomedicines
WO2017050979A1 (en) Nanoparticles for diagnosis and drug delivery
US10035806B2 (en) Derivatized corroles and metallocorroles and their use as imaging and therapeutic agents
Ding et al. A tumor-targeting drug delivery system based on cyclic NGR-modified, combretastatin A4-loaded, functionalized graphene oxide nanosheets
RU2773707C2 (ru) Наноконъюгаты доксорубицин-золото направленного воздействия для терапии опухолей
HK40014034A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220120

R150 Certificate of patent or registration of utility model

Ref document number: 7017258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees